To appraise the clinical and cost effectiveness of enzalutamide within its marketing authorisation for treating non-metastatic hormone-relapsed prostate cancer.
Status In progress
Process STA pre-2018
ID number 1359

Provisional Schedule

Committee meeting: 2 19 February 2019

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Aberdeen HTA Group


Companies sponsors Astellas Pharma (enzalutamide)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Prostate Cancer UK
Professional groups Association of Cancer Physicians
  British Uro-Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord (bicalutamide) not participating
  AstraZeneca UK (bicalutamide, goserelin) not participating
  Bayer (cyproterone acetate)
  Concordia International (leuprorelin) not participating
  Ferring Pharmaceuticals (degarelix, triptorelin) not participating
  Generics UK T/A Mylan (flutamide)
  Ipsen (triptorelin) not participating
  Orion Pharma UK (histrelin) not participating
  Sanofi (buserelin) not participating
  Sunpharma (bicalutamide) not participating
  Takeda UK (leuprorelin) not participating
  Wockhardt UK (cyproterone acetate) not participating
  Zentiva (bicalutamide) not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute


Key events during the development of the guidance:

Date Update
24 January 2019 - 14 February 2019 Appraisal consultation
04 December 2018 Committee meeting: 1
13 July 2018 Invitation to participate
14 February 2018 - 14 March 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2017 In progress, Ref received from DH

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance